Published in Hepatitis Weekly, November 22nd, 1999
VX-497 is an inhibitor of inosine monophosphate dehydrogenase (IMPDH) being developed by Vertex Pharmaceuticals Inc.
Preliminary Phase II data for VX-497 indicate that the drug was well-tolerated and resulted in reduced levels of serum alanine aminotransferase (ALT), a marker of liver inflammation, in HCV patients treated for 28 days.
Vertex is now beginning...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.